Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group.
Brice P, Divine M, Simon D, Coiffier B, Leblond V, Simon M, Voilat L, Devidas A, Morschhauser F, Rohrlich P, André M, Lepage E, Ferme C. Brice P, et al. Among authors: divine m. Ann Oncol. 1999 Dec;10(12):1485-8. doi: 10.1023/a:1008343823292. Ann Oncol. 1999. PMID: 10643540 Free article. Clinical Trial.
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, Voillat L, Jaubert J, Lederlin P, Colin P, Berger F, Salles G. Fermé C, et al. Among authors: divine m. J Clin Oncol. 2002 Jan 15;20(2):467-75. doi: 10.1200/JCO.2002.20.2.467. J Clin Oncol. 2002. PMID: 11786576 Clinical Trial.
Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Morschhauser F, et al. Among authors: divine m. J Clin Oncol. 2008 Dec 20;26(36):5980-7. doi: 10.1200/JCO.2007.15.5887. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018090 Clinical Trial.
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J, Blay JY, Voillat L, Lederlin P, Stamatoullas A, Bienvenu J, Guiguet M, Intrator L, Grandjean M, Brière J, Ferme C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte. Casasnovas RO, et al. Among authors: divine m. J Clin Oncol. 2007 May 1;25(13):1732-40. doi: 10.1200/JCO.2006.08.1331. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389336
Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P. Brice P, et al. Among authors: divine m. Bone Marrow Transplant. 1997 Jul;20(1):21-6. doi: 10.1038/sj.bmt.1700838. Bone Marrow Transplant. 1997. PMID: 9232251
122 results